Prosecution Insights
Last updated: April 19, 2026
Application No. 18/506,518

ANTIGEN-BINDING PROTEINS TARGETING MELANOMA DIFFERENTIATION ANTIGENS AND USES THEREOF

Non-Final OA §103
Filed
Nov 10, 2023
Examiner
JOHANSEN, PETER N.
Art Unit
1644
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Memorial Sloan-Kettering Cancer Center
OA Round
3 (Non-Final)
60%
Grant Probability
Moderate
3-4
OA Rounds
2y 11m
To Grant
85%
With Interview

Examiner Intelligence

Grants 60% of resolved cases
60%
Career Allow Rate
122 granted / 202 resolved
At TC average
Strong +25% interview lift
Without
With
+24.6%
Interview Lift
resolved cases with interview
Typical timeline
2y 11m
Avg Prosecution
48 currently pending
Career history
250
Total Applications
across all art units

Statute-Specific Performance

§101
4.2%
-35.8% vs TC avg
§103
34.2%
-5.8% vs TC avg
§102
15.9%
-24.1% vs TC avg
§112
27.5%
-12.5% vs TC avg
Black line = Tech Center average estimate • Based on career data from 202 resolved cases

Office Action

§103
The examiner of this application in the PTO has changed. To aid in correlating any papers for this application, all further correspondence regarding this application should be directed to Peter Johansen, Group Art Unit 1642, Technology Center 1600. Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Continued Examination Under 37 CFR 1.114 A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on March 2, 2026 has been entered. By way of this submission, Applicant has amended claim 60. Claims 60-61, 66-67, 74-78, and 87-95 are pending in the application and under examination before the Office. The rejections of record can be found in the previous Office action, dated September 2, 2025. In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claims 60-61, 66-67, 74-75, and 87-95 are rejected under 35 U.S.C. 103 as being unpatentable as being unpatentable over Olivares (WO2015123642A1) in view of Balderes (WO2009114585A1) and Houghton (WO199640249). Olivares teaches a chimeric antigen receptor (CAR) that binds GP75 (also known as Trp1 and TYRP1, see page 20 of the instant specification), based upon a binding domain TA99 (Table 1, para. 0021). Applicant's specification states that the scFv used is based on TA99 (see pages 24 and 65 of the instant specification). Olivares further teaches said CAR comprises an extracellular antigen-binding domain, a transmembrane domain and an endodomain (i.e., an intracellular domain) (para. 0023). Olivares further teaches that said CAR and cells and pharmaceutical compositions comprising such are useful for treating cancer (para. 0005 and 0073), and are useful in killing tumor cells (para. 0002), which is pertinent to claim 61. Olivares further teaches that the cancer is melanoma, and the subject is human (para. 0015), which is pertinent to claims 66-67 and 74. Olivares further teaches that said CAR may be expressed in T cells (e.g., para. 0009), which is pertinent to claim 75. Olivares further teaches that the extracellular antigen-binding domain may be an scFv (para. 0008 and 0086), which is pertinent to claim 87. Olivares further teaches that the transmembrane domain may be a CD8 domain (para. 0083 and 00126), which is pertinent to claims 88-89. Olivares further teaches that the intracellular domain may be a CD3zeta domain (para. 0008, 0022, 00114 and 00130), which is pertinent to claim 90. Olivares further teaches that the intracellular domain may also comprise a CD28 co-stimulatory domain (para. 0008 and 0084), which is pertinent to claims 91-93. Olivares further teaches that the T cell expressing the above CAR may be an NKT cell (para 0014), which is pertinent to claim 95. However, Olivares does not teach the claimed sequences of the antigen-binding domain. Balderes teaches antibodies that bind to TYRP1 with identical complementarity determining regions to that of a humanized version of TA99 (CTA99) (page 3, line 28 through page 4, line 7, and page 24, line 21-29). These complementarity determining regions are enumerated as SEQ ID NOs: 7-12 in Balderes, and are identical to the complementarity determining regions of the chimeric antigen receptor antigen-binding domain used in the claimed method (see Applicant's SEQ ID NOs: 1-6). Balderes further teaches scFvs of the above antibody (page 9, line 17 through page 10, line 4). Balderes further teaches that antibodies substantially homologous to CTA99 can be readily designed and manufactured utilizing various recombinant DNA techniques well known to those skilled in the art (page 11, line 29 through page 12, line 7). Balderes further teaches that CTA99 is effective at treating human melanoma (page 30, lines 4 through page 32, line 17). Houghton teaches that antibody TA99 is useful in treating melanoma (e.g., Figure 1). It would have been prima facie obvious for a person of ordinary skill in the art as of the effective filing date to combine the teachings of Olivares, Balderes, and Houghton to arrive at the claimed invention. An ordinary artisan would have been motivated to do so, and have a reasonable expectation of success, since all of Olivares, Balderes, and Houghton are concerned with using the anti-Trp1 antibody TA99 for the treatment of melanoma. Starting with the method of treatment using CAR-T cells based upon the TA99 scFV taught by Olivares, one of ordinary skill could follow guidance in both Balderes and Houghton concerning the TA99 antibody to arrive at the claimed method. Each component of the combination would perform its known, usual function, and the combination would yield nothing more than predictable results. While the references do not explicitly teach the claimed light and heavy chain sequences, Applicant's specification states that the scFv used is based on TA99, as described in the Houghton reference (see pages 24 and 65 of the instant specification). As Houghton discloses TA99, the light and heavy chain sequences of this antibody must also be present. The ordinary artisan using the TA99 antibody or scFV would also inherently be using the same sequences. Furthermore, Balderes teaches an exemplary scFv with complementarity determining regions that are identical to the complementarity determining regions of the chimeric antigen receptor antigen-binding domain used in the claimed method. Balderes also teaches that antibodies substantially homologous to CTA99 can be readily designed and manufactured utilizing various recombinant DNA techniques well known to those skilled in the art. It would therefore be obvious to utilize these correctly defined CTA99 CDR regions in a chimeric antigen receptor which is directed to the TYRP1 protein for the purposes of utilizing the correct, previously heterogeneously defined VL "TA99" which has improved activity and a higher affinity for the TYRP1 molecule to create a more effective antigen binding chimeric antigen receptor molecule as described by Balderes. Applicant argues that the skilled artisan, in view of the common knowledge in the art, would not have been motivated to develop a method of treating cancer targeting Trp1, as such treatment were known to show failure of treatments and off-target toxicities, citing reference to Muranski (Blood, The Journal of the American Society of Hematology, 112.2 (2008): 362-373). Applicant further argues that Balderes states that the unacceptably toxicity of TA99 would make it unacceptable for use as a therapeutic in humans. Applicant's arguments have been considered fully but are not found to be persuasive. Muranski teaches a T cell which binds through an engineered T cell receptor. Balderes teaches only an antibody. Neither of these references teaches chimeric antigen receptors. Furthermore, contrary to Applicant's assertion, Muranski teaches that Th17-polarized TRP-1 cells are highly efficient in mediating the rejection of established B16 melanoma tumor upon adoptive cell transfer (Figure 4). Balderes is also explicit that TA99-based treatments are useful in the treatment of melanoma (page 5, lines 6-11, also see page 30, lines 4-16). Balderes also teaches that TA99 can be modified for more suitable use in humans (page 24, lines 28-29). The guidance of Balderes would direct one of ordinary skill to make humanized versions of TA99 that solve the problem of any toxicity in targeting Trp1. It is also noted that this argument was not found persuasive in the previous Office action, dated September 2, 2025. Applicant's arguments also raise questions of enablement, since the CAR construct used in the claimed method is based upon TA99 and targets Trp1, and Applicant has not explained why their method is free from the asserted problems of other such methods replying upon targeting Trp1. This rejection is therefore maintained. Claims 76-78 are rejected under 35 U.S.C. 103 as being unpatentable over Olivares, Balderes and Houghton as applied to claim 60 above, and further in view of June (WO2012079000). The teachings of Olivares, Balderes and Houghton have been described supra. However, Olivares, Balderes and Houghton do not teach administering cyclophosphamide. June teaches a method of treating a cancer, comprising administering a CAR-T cell therapy (e.g., page 5, lines 21-34). June further teaches that the CAR may target TRP-1 (page 29, line 18). June further teaches that the cancer to be treated may be melanoma (page 50, line 16). June further teaches that the CAR-T therapy may be administered in combination with cyclophosphamide (page 55, lines 15-20). It would have been prima facie obvious for a person of ordinary skill in the art as of the effective filing date to combine the teachings of Olivares, Balderes, Houghton, and June to arrive at the claimed invention. As stated above, CAR-T treatments for melanoma using Trp-1 targeting antigen-binding domains were known, according to Olivares, Balderes and Houghton. June teaches that cyclophosphamide may be administered in combination with CAR-T treatment. One of ordinary skill would therefore be motivated to combine the cyclophosphamide of June with the CAR-T cell of Olivares, Balderes and Houghton. Each component of the combination would perform its known, usual function, and the combination would yield nothing more than predictable results. Applicant argues that June does not remedy the alleged deficiencies of Olivares, Balderes and Houghton. This is not found persuasive, for reasons described supra. This rejection is therefore maintained. Conclusion No claim is allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to PETER JOHANSEN whose telephone number is (571)272-0280. The examiner can normally be reached Monday-Friday, 7:00 to 3:00. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Samira Jean-Louis can be reached at (571) 270-3503. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /PETER JOHANSEN/Examiner, Art Unit 1644
Read full office action

Prosecution Timeline

Nov 10, 2023
Application Filed
Jul 01, 2024
Response after Non-Final Action
Sep 12, 2024
Response after Non-Final Action
Nov 29, 2024
Non-Final Rejection — §103
Jun 05, 2025
Response Filed
Aug 27, 2025
Final Rejection — §103
Mar 02, 2026
Request for Continued Examination
Mar 06, 2026
Response after Non-Final Action
Mar 23, 2026
Non-Final Rejection — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12600765
NOVEL TARGET FOR ANTI-CANCER AND IMMUNE-ENHANCING
2y 5m to grant Granted Apr 14, 2026
Patent 12601748
PROSPECTIVE MARKERS IN TRAUMATIC BRAIN INJURY (TBI)
2y 5m to grant Granted Apr 14, 2026
Patent 12594324
METHODS AND COMPOSITIONS FOR TREATMENT OF PANCREATIC CANCER
2y 5m to grant Granted Apr 07, 2026
Patent 12576148
Engineered immune effector cells for cancer immunotherapy that are resistant to fratricide by virtue of having genetically modified surface antigens
2y 5m to grant Granted Mar 17, 2026
Patent 12570958
SINGLE- AND MULTI-CHAIN CHIMERIC ANTIGEN RECEPTORS
2y 5m to grant Granted Mar 10, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

3-4
Expected OA Rounds
60%
Grant Probability
85%
With Interview (+24.6%)
2y 11m
Median Time to Grant
High
PTA Risk
Based on 202 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month